沈阳药科大学获批国家药监局监管科学创新研究基地

Group 1 - Shenyang Pharmaceutical University has been approved as a "National Medical Products Administration Regulatory Science Innovation Research Base (Chemical Drug Field)," marking its entry into the national strategic echelon in the field of chemical drug regulatory science [1] - The National Medical Products Administration has approved a total of 29 regulatory science innovation research bases across various fields, including traditional Chinese medicine, chemical drugs, biological products, medical devices, cosmetics, and common research [1] - The university will collaborate with the Liaoning Provincial Inspection and Testing Certification Center and the Heilongjiang Provincial Drug Inspection Research Institute to integrate testing and inspection technology resources and establish a cross-regional research collaboration mechanism [1] Group 2 - The base will focus on quality control, change management, and intelligent regulatory technologies for chronic disease treatment drugs and complex formulations, as well as quality control technologies and dependency evaluations for narcotic and psychotropic drugs [2] - By establishing a regulatory science innovation research platform for chronic diseases, narcotic drugs, and psychotropic drugs, the base aims to promote innovation in regulatory tools, standards, and methods throughout the lifecycle of chemical drugs [2] - The base will align with the actual regulatory needs of China's chemical drugs, benchmark against international regulatory science developments, and rely on a "government-industry-university-research-application" collaborative mechanism to create a comprehensive innovation system from theoretical research to technology transfer, policy support, and talent cultivation [2]